Consensus report: Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 8, 2002, Pages 1407-1430

  Camilleri, M ^a   Heading, R C ^b   Thompson, W G ^c  

^a MAYO CLINIC   (United States)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORDIAZEPOXIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CLIDINIUM; COLESTYRAMINE; DIPHENOXYLATE; KAPPA OPIATE RECEPTOR AGONIST; LOPERAMIDE; MEBEVERINE; MIANSERIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; OPIATE; OSMOTIC AGENT; OTILONIUM BROMIDE; PSYCHOTROPIC AGENT; QUATERNARY AMMONIUM DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SOMATOSTATIN DERIVATIVE; SPASMOLYTIC AGENT; TRIMEBUTINE; UNINDEXED DRUG; SEROTONIN AGONIST;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIETARY FIBER; DRUG CHOICE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FOOD INTAKE; GASTROINTESTINAL MOTILITY; HUMAN; HYPNOSIS; IRRITABLE COLON; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL ASPECT; TREATMENT PLANNING; ADULT; AGED; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; COST OF ILLNESS; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; ANTIDIARRHEALS; COLONIC DISEASES, FUNCTIONAL; COST OF ILLNESS; DIETARY FIBER; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SEROTONIN AGONISTS;

EID: 0036686754     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01305.x     Document Type: Review

References (236)

1. Towards a positive diagnosis of the irritable bowel
2. Irritable bowel syndrome: Guidelines for the diagnosis
3. Functional bowel disorders and functional abdominal pain
4. The irritable bowel syndrome: Mechanisms and a practical approach to management
5. Irritable bowel syndrome: A technical review for practice guideline development
6. Review article: Irritable bowel syndrome
7. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact
8. Irritable bowel syndrome in a community: Symptom subgroups, risk factors and health care utilization
9. Functional digestive disorders (FDD) in the year 2000 - Economic impact
10. Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures
11. The role of psychological and biological factors in postinfective gut dysfunction
12. Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome
13. Anorectal manometry in irritable bowel syndrome: Differences between diarrhea and constipation predominant subjects
14. Altered rectal perception is a biological marker of patients with irritable bowel syndrome
15. Controlled treatment trials in the irritable bowel syndrome: A critique
16. Symptoms of psychologic distress associated with irritable bowel syndrome
17. Sexual and physical abuse and gastrointestinal illness. Reviews and recommendations
18. Rome II: A multinational consensus document on functional gastrointestinal disorders
19. Agreement between Rome I and Rome II diagnostic criteria for IBS
20. Irritable bowel syndrome defined by factor analysis: Gender and race comparisons
21. Diagnostic value of the Manning criteria in irritable bowel syndrome
22. Gender differences in Manning criteria in the irritable bowel syndrome
23. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
24. A comparison of the prevalence of IBS using Rome I and Rome II criteria in an epidemiological survey
25. Comparing Rome I and Rome II criteria for irritable bowel syndrome (IBS) in a prospective survey of the Canadian population
26. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates
27. A comparison of the prevalence of irritable bowel syndrome (IBS)-type symptoms in anxiety disorder out-patients using Rome I and Rome II criteria
28. Does irritable bowel syndrome diagnosis change with the Rome II diagnostic criteria?
29. Agreement between clinician recorded diagnoses and Rome I and Rome II diagnostic criteria for irritable bowel syndrome
30. A pilot study of motility and tone of the left colon in diarrhea due to functional disorders and dysautonomia
31. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases
32. Pain is temporarily related to eating but not to defecation in irritable bowel syndrome (IBS). Patients' descriptions of diarrhea, constipation and symptom variation during a prospective 6-week study
33. Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea
34. Transition probabilities between functional gastrointestinal disorders in the community
35. Prevalence of gastrointestinal symptoms in the elderly: A population-based study
36. The incidence of clinically diagnosed irritable bowel syndrome in the community
37. Clinical profile of irritable bowel syndrome at a rural based teaching hospital in central India
38. Gender variations in clinical pain experience
39. Sex differences in pain
40. Changes in skin and muscle sensitivity in dysmenorrheic vs. normal women as a function of body site and monthly cycle
41. Differences between males and females in rates of serotonin synthesis in human brain
42. Irritable bowel symptoms in spontaneous and induced constipation
43. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
44. Epidemiology of constipation (EPOC) study in the United States: Relation of clinical subtypes to sociodemographic features
45. Pelvic floor function/dysfunction and electrodiagnostic evaluations
46. Laxative consumption in chronic nonorganic constipation
47. Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals
48. Evidence for exacerbation of irritable bowel syndrome during menses
49. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle
50. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments
51. Irritable bowel syndrome and chronic pelvic pain
52. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome
53. Bladder smooth muscle dysfunction in patients with irritable bowel syndrome
54. Functional somatic symptoms: One or many?
55. Weakness of the pelvic floor: Urological consequences
56. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom
57. The impact of irritable bowel syndrome on health-related quality of life
58. Validation of a specific quality of life questionnaire for functional digestive disorders
59. Further validation of the IBS-QOL: A disease-specific quality of iife questionnaire
60. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life
61. Irritable bowel syndrome in office-based practice in the United States
62. Irritable bowel syndrome in general practice: Prevalence, characteristics, and referral
63. Medical costs in community subjects with irritable bowel syndrome
64. Longitudinal study of the comparative costs of IBS in an HMO
65. Intergenerational transmission of gastrointestinal illness behavior
66. Clinical economics review: Irritable bowel syndrome
67. Costs associated with healthcare resource use and productivity loss in patients with irritable bowel syndrome (IBS)
68. Motility disorders and stress
69. Alterations in man in colonic functions under stress. Experimental production of changes simulating the 'irritable colon'
70. Colonic scintigraphy and manometry in constipation, diarrhea and inflammatory bowel disease
71. Postprandial colonic transit and motor activity in chronic constipation
72. Effect of bile acid perfusion on colonic motor function in patients with the irritable colon syndrome
73. Irritable bowel syndrome, relationship of disorders in the transit of a single solid meal to symptom patterns
74. Transit through the proximal colon influences stool weight in the irritable bowel syndrome
75. Scintigraphic measurement of regional gut transit in idiopathic constipation
76. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
77. Ambulatory small intestinal motility in diarrhea predominant irritable bowel syndrome
78. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
79. Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients
80. Role of psychologic symptoms in irritable bowel syndrome: Comparison of community and clinic samples
81. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders
82. Scintigraphy of the whole gut: Clinical evaluation of transit disorders
83. Rapid gastric emptying in patients with functional diarrhea
84. Basic and clinical aspects of visceral hyperalgesia
85. Regional cerebral activity in normal and pathological perception of visceral pain
86. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention
87. The coexistence of fibromyalgia (FM) alters rectal perception before and after sigmoid stimulation in female IBS patients
88. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects
89. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients
90. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities
91. Ways in which emotion can affect the digestive tract. Helps in sizing up the patient
92. Psychological significance of the irritable colon syndrome
93. Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction
94. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome
95. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon
96. Increased colonic motility during exposure to a stressful situation
97. Can panic disorder present as irritable bowel syndrome?
98. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
99. Irritable bowel syndrome and psychiatric illness
100. Psychosocial aspects of the functional gastrointestinal disorders
101. Psychosocial factors in the irritable bowel syndrome: A multivariate study of patients and nonpatients with irritable bowel syndrome
102. Psychological factors in functional gastrointestinal disorders: Characteristics of the disorder or of the illness behavior?
103. Panic disorder and gastrointestinal symptoms: Findings from the NIMH Epidemiologic Catchment Area Project
104. More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology
105. Fibromyalgia in the irritable bowel syndrome: Studies of the prevalence and clinical implications
106. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome
107. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices
108. Self-reported abuse and gastrointestinal disease in outpatients: Association with irritable bowel-type symptoms
109. Gastrointestinal tract symptoms and self-reported abuse: A population-based study
110. Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid
111. Short-chain fatty acids stimulate motility of the canine ileum
112. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhea
113. Food intolerance, a major factor in the pathogenesis of irritable bowel syndrome
114. Food intolerance and the irritable bowel syndrome
115. Intestinal gas dynamics and tolerance in humans
116. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome
117. Stimulation of intestinal gas propulsion is the key to treat gas retention in functional patients
118. Abnormal colonic fermentation in irritable bowel syndrome
119. Irritable bowel syndrome - Post salmonella infection
120. Psychological scores and persistence of irritable bowel after infectious diarrhea
121. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients
122. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study
123. Stress-induced visceral hypersensitivity to rectal distension in rats: Role of CRF and mast cells
124. IL-10 and TGF-B genotypes in irritable bowel syndrome: Evidence to support an inflammatory component?
125. Is there an inflammatory basis for a subset of patients presenting with diarrhea in the irritable bowel syndrome
126. Increased rectal mucosa enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome
127. Postinfective diarrhea and bile acid malabsorption
128. Terminal ileal mucosal mast cells in irritable bowel syndrome
129. Increased mast cells in the irritable bowel syndrome
130. Increased iNOS and nitrosotyrosine expression in irritable bowel syndrome
131. On the mechanism underlying post-infective intestinal dysfunction
132. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice
133. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease
134. The irritable bowel syndrome: Mechanisms and a practical approach to management
135. Prevention of colorectal cancer: Guidelines based on new data. WHO collaborating center for the prevention of colorectal cancer
136. Colorectal cancer screening: Clinical guidelines and rationale
137. Screening guidelines for colorectal cancer
138. Colorectal cancer screening in the UK: Joint position statement by the British Society of Gastroenterology
139. British Society of gastroenterology guidelines for the management of the irritable bowel syndrome
140. Irritable bowel syndrome. Diagnosis in the managed care era
141. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome?
142. Is rectal biopsy necessary in irritable bowel syndrome?
143. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling Rome criteria
144. Diagnosing and treating patients with refractory functional gastrointestinal disorders
145. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
146. Symptom survey in patients with irritable bowel syndrome
147. Prognosis in the irritable bowel syndrome: A 5-year prospective study
148. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction
149. Irritable bowel syndrome: The view from general practice
150. Irritable bowel syndrome - A safe diagnosis?
151. Irritable bowel syndrome - Prognosis and diagnostic safety. A 5-year follow-up study
152. Prognosis in the irritable bowel syndrome. A prospective study
153. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
154. The epidemiology of irritable bowel syndrome in a random population: Prevalence, incidence, natural history and risk factors
155. Clinical management of intractable constipation
156. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
157. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
158. Treatment of irritable bowel syndrome: A review of randomized controlled trials
159. Comparison of diet composition in women with and without functional bowel disorder
160. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
161. Effect of wheat bran on weight of stool and gastrointestinal transit time: A meta-analysis
162. Gastric wall tension determines perception of gastric distention
163. 2-adrenergic agents in humans
164. Pharmacological modulation of rectal tone alters perception of distention in humans
165. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study
166. Bran supplementation in the treatment of irritable bowel syndrome
167. Bran and irritable bowel syndrome: Time for reappraisal
168. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome
169. The role of intestinal gas in functional abdominal pain
170. Is the irritable bowel really irritable?
171. Tolerance for rectosigmoid distention in irritable bowel syndrome
172. Impaired ascending colon clearance in response to rapid small bowel transit in bloated irritable bowel syndrome: Bran exaggerates the problems
173. Pharmacology of dietary fibre
174. Artificial fiber complexes composed of cellulose and guar gum or psyllium may be better sources of soluble fiber for rats than comparable fiber mixtures
175. Is bran efficacious in irritable bowel syndrome? A double-blind, placebo-controlled crossover study
176. Need of the ideal drug for the treatment of chronic constipation
177. Clinical response to dietary fiber treatment of chronic constipation
178. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent abdominal pain: Results in a prospective, double-blind, randomized, controlled trial
179. Irritable bowel patients and their long-term response to a high fiber diet
180. Role of loperamide and placebo in management of irritable bowel syndrome
181. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency
182. Idiopathic bile salt catharsis
183. Double-blind crossover study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea
184. Idiopathic bile acid malabsorption: Long-term outcome
185. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhea
186. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhea and its correlation with small bowel transit
187. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis
188. Antidepressants for functional gastrointestinal syndromes
189. Treatment of functional gastrointestinal disorders with antidepressants, a meta-analysis
190. Irritable colon and depression
191. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity
192. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans
193. The effect of trimipramine in patients with the irritable bowel syndrome
194. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome
195. The effects of desipramine on IBS compared with atropine and placebo
196. Comparison of various treatments for irritable bowel syndrome
197. Fluoxetine
198. Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials
199. A controlled trial of psychological treatment for the irritable bowel syndrome
200. Hypnotherapy in the irritable bowel syndrome
201. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
202. 3-receptor antagonist
203. 3-receptor antagonist
204. Efficacy and safety of alosetron in women with irritable bowel syndrome, a randomised, placebo-controlled trial
205. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
206. Ischemic colitis during treatment with alosetron
207. 4 receptor agonist
208. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists
209. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
210. 4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying
211. Effects of tegaserod (HTF 919) on gastrointestinal motility and transit in awake rats
212. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome
213. Discharge patterns of intramural mechanoreceptive afferents during selective distension of the cat's rectum
214. 4 receptor partial agonist
215. 4 receptor partial agonist, on colorectal distension in rats
216. 4 receptor
217. 4 receptor partial agonist tegaserod (HTF 919) improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome (IBS)
218. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
219. 4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS)
220. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919
221. 4 partial agonist, tegaserod, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS)
222. Short and long-term safety and tolerability of tegaserod in patients with IBS
223. Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS)
224. Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug, in healthy subjects and patients with hepatic cirrhosis
225. Pharmacokinetics (PK) of SDZ HTF 919 not altered in subjects with severe renal insufficiency requiring hemodialysis
226. Effect of a novel prokinetic drug, R093877. On gastrointestinal transit in healthy volunteers
227. 4 agonist, prucalopride, in healthy humans
228. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
229. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: Results of two double-blind, placebo-controlled trials
230. Irritable bowel syndrome
231. Efficacy of peripheral kappa agonist, fedotozine, versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
232. Adrenergic modulation of human colonic motor and sensory function
233. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia. Effect on symptoms and gastric sensory and motor function
234. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man
235. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome
236. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial